Cancer cell-derived exosomes expressing TGF-β can downregulate NKG2D expression on NK and CD8+ T cells, while other receptors, including CD4, CD8, CD56, CD16, CD69, and CD94 are not affected, indicating the selectivity of the effect [44,45,46,47]. This evidence concerns the gene TGFB1 and cancer.